Compare EPSN & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPSN | IVVD |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.2M | 201.9M |
| IPO Year | 2018 | 2021 |
| Metric | EPSN | IVVD |
|---|---|---|
| Price | $5.60 | $1.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 130.2K | ★ 3.5M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | N/A | $61.57 |
| Revenue Next Year | N/A | $41.42 |
| P/E Ratio | $21.71 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $4.20 | $0.52 |
| 52 Week High | $6.65 | $3.07 |
| Indicator | EPSN | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 69.89 |
| Support Level | $5.53 | $0.69 |
| Resistance Level | $5.62 | $1.01 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 45.52 | 89.30 |
Epsilon Energy Ltd is a North American on-shore focused independent natural gas and oil company engaged in the acquisition, development, gathering and production of natural gas and oil reserves. Its properties include Appalachian Basin-Pennsylvania, Permian Basin-Texas and New Mexico, Anadarko Basin-Oklahoma, Powder River Basin-Wyoming, Western Canadian Sedimentary Basin-Alberta, Canada. Its segments include The Upstream segment activities include acquisition, development and production of natural gas and oil reserves on properties within the United States and Canada; and The Gas Gathering segment partners with two other companies to operate a natural gas gathering system. The Upstream segment derives the majority of the revenue.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.